Chembio Diagnostics, Inc. (CEMI) Starts Presentation at LD Micro Conference

Chembio Diagnostics develops, manufactures, licenses and markets proprietary rapid diagnostic tests in the point-of-care testing market. Chembio’s two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Alere, Inc. Chembio markets its HIV STAT-PAK® line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP®) technology, which has significant advantages over lateral-flow technologies. For more information, visit the company’s website at www.chembio.com.